Olaris, a leader in metabolomics and precision medicine, announced a strategic investment from Bruker Corporation (Nasdaq: BRKR), a global leader in scientific instrumentation and diagnostics solutions. The investment will support the continued development and commercialization of Olaris' proprietary metabolomics platform, which leverages machine learning and metabolite biomarker discovery to revolutionize how diseases are diagnosed, treated, and monitored..

奥拉里斯（Olaris）是代谢组学和精准医疗领域的领导者，近日宣布获得来自全球科学仪器和诊断解决方案领导者布鲁克公司（Bruker Corporation，纳斯达克代码：BRKR）的战略投资。该投资将推动奥拉里斯专有代谢组学平台的持续开发与商业化，该平台利用机器学习和代谢生物标志物发现技术，彻底改变疾病的诊断、治疗和监测方式。